Skip to main content
. 2018 Oct 19;23(1):380–394. doi: 10.1111/jcmm.13942

Figure 2.

Figure 2

Madecassoside (MA) suppresses RANKL‐induced osteoclastogenesis in the early stages. (A‐B) Representative images of TRAcP+ cells treated with 10 μmol L−1 MA on the indicated days (magnification = 4×). (C) TRAcP‐stained cells (>3 nuclei) treated with MA at different time periods were quantitatively analyzed for osteoclast formation. Data are presented as the means ± SD; *P < 0.05, **P < 0.01, and ***P < 0.001 relative to RANKL‐induced controls